Answers are grounded in this paper and cite their sources.
In this issue, Greub et al. show that discriminate prescribing and utilization of HIV post-exposure prophylaxis (PEP) is sensible from a pharmaco-economic point of view [1]. They investigate a policy of active approaching and HIV-testing of source persons after non-occupational HIV exposures (sexual or addictive drug use) in Lausanne, Switzerland. This policy avoided over 90% of unnecessary PEP prescribing. In the corresponding pharmaco-economic simulation model they estimate that the approaching/testing policy achieves a 31% cost reduction in comparison with the absence of such a policy. In this editorial, we focus on the relevance of discriminate prescribing in general, with the policy suggested by Greub et al. being one option incorporated in current guidelines. Furthermore, we argue that inclusion of adverse drug reactions (ADRs) of PEP would further improve the modelled pharmaco-economic outcome of discriminate prescribing. The pharmaco-economic simulation model applied by Greub et al. follows the design of a cost-minimization analysis [1]. Cost-minimization analysis relates monetary costs and benefits, the difference being labelled as net costs (or net benefits if negative). Greub et al. estimate costs for several types of activities, such as HIV testing and consultations. Monetary benefits primarily relate to avoided costs of the prophylaxis with zidovudine, lamivudine and nelfinavir. Benefits due to averted ADRs of PEP are mentioned in their discussion, but not formally included in the cost minimization model. Cost minimization is one of three broadly used types of pharmaco-economic analysis, the others being cost-effectiveness and cost-utility analysis [2]. Cost- effectiveness analysis relates the net costs to some physical unit, such as HIV-infections averted or life-years gained. Cost-utility analysis extends cost- effectiveness with a measure for quality of life, with the typical outcome being net costs per quality-adjusted life-year (QALY) gained. All three types of analysis can be found in the literature on HIV PEP [3,4]. Using the concept of net costs per QALY gained, HIV prophylaxis after sexual exposure has been previously addressed in this journal [3]. As found by Greub et al. [1], discriminate prescribing of PEP significantly enhanced the pharmaco-economic profile of PEP. Prescribing was discriminated with respect to probability of HIV-infection in the source and type of sexual activity (vaginal versus anal and insertive versus receptive). In the population considered – with a probability of HIV-infection in the source person of 18% – cost-utility was estimated at US$ 6300 per QALY saved for receptive anal intercourse. For insertive intercourse however, PEP was estimated not to be cost-effective (net costs per QALY exceeding US$ 100 000) [3]. Greub et al. [1] did not include the type of sexual activity in their analysis nor the presence of other sexually transmitted infections (co-infections), potentially enhancing transmissibility of HIV [5]. Inclusion of these parameters in the analysis may enable further targeting of PEP and further specification of pharmaco-economic outcomes of discriminate prescribing. The Centers for Disease Control recommend discriminate prescribing of PEP after non-occupational HIV exposures only for those exposures that carry a high risk for infection [6]. An inventory of PEP policies in European countries showed that in 1999 many countries still lacked any national guidelines or recommendations and reimbursement arrangements on HIV prophylaxis after non-occupational exposures [7]. In many countries, prescribing of PEP was the individual physician's decision and costs were often born by the patient. Only a few countries (for example, France and Germany) had nationally specified formal risk assessment criteria to justify prescribing of PEP after a non- occupational exposure. Currently, several countries – such as the Netherlands – are developing guidelines for PEP after non-occupational exposure, including formal criteria for discriminate prescribing, such as probability of HIV-infection in the source, type of sexual exposure and presence of co-infections [8]. In this context, the probability of HIV-infection in the source is preferably assessed through testing or estimated using the ‘background prevalence'. In contrast to the absence of national guidelines for non-occupational exposures, almost all European countries surveyed in 1999 already had national recommendations or guidelines for HIV prophylaxis after occupational exposures [7]. These guidelines always discriminate between the types of exposure, the severity of the injury and the likelihood of HIV-infection in the source patient. As with Greub et al. [1], most pharmaco-economic analyses of PEP, did not include the costs and negative health effects of ADRs to PEP [1,3,9]. However, ADRs are generally considered to be a major problem in prescribing PEP. Major ADRs have been reported, including diabetes, nefrolithiasis, hyperbilirubinemia, pancreatitis or hepatitis [10]. Recently, a case report described a healthcare worker taking nevirapine after an occupational exposure, who afterwards required a liver transplant for life-threatening liver damage [11]. Minor ADRs, such as nausea and headache also often occur and may result in discontinuation of prophylaxis. Adding costs and negative health effects of ADRs to the existing pharmaco-economic models would obviously further improve the pharmaco-economic profile of discriminate prescribing of PEP. Typically, lifetime costs of the consequences of ADRs – for example, based on a theoretical model for PEP-related diabetes – would have to be included in the monetary benefits of discriminate prescribing [12,13]. Summarizing, a favourable pharmaco-economic profile of targeted/discriminate prescribing of PEP is shown in all types of pharmaco-economic analysis. All recent formal guidelines explicitly include discriminate prescribing, by distinguishing between the HIV-status of the source, type of exposure and the presence of co-infections. From a clinical pharmaceutical point of view, knowledge of the source subject's HIV-status and the antiretroviral treatment history makes it possible to tailor drug-prescribing to a regimen that is most likely to benefit the patient considering the growing problem of drug resistance [14]. Given the ADRs, discriminate prescribing of PEP is in line with one of any physician's starting points to prescribe; i.e. ‘primum non nocere’ (or: firstly, let's not harm the patient). In conclusion, there is much to be gained by discriminate prescribing of PEP, from both the medical/pharmaceutical and the pharmaco-economic perspective. Inclusion of costs and effects of ADRs in the pharmaco-economic model, further improves estimated pharmaco-economic outcome of discriminate prescribing. An active approach by testing the source – as analysed by Greub et al. [1] in this issue – presents one option for discriminate prescribing. Other options should be pursued as well, to further enhance the pharmaco-economic profile of PEP.
No takes yet. Share an insight, caveat, or question.
Postma et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: